Radiation boost may help immunotherapy fight lung cancer
NCT ID NCT03176173
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding high-dose, precisely targeted radiation to standard immunotherapy can improve outcomes for people with stage IV non-small cell lung cancer. Forty-five adults who were already on immunotherapy received radiation to some of their tumors. Researchers measured how long the cancer stayed under control and whether tumors shrank.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
image-guided radiation therapy (IGRT) plus immunotherapy (anti-PD-1 or anti-PD-L1)
What this could lead to
If it works, this combination could help control metastatic lung cancer better than immunotherapy alone.
What could go wrong
This is a small, completed phase II trial with only 45 participants. Results may not apply to all patients, and radiation can cause side effects like fatigue or lung inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University, School of Medicine
Palo Alto, California, 94304, United States